<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03276858</url>
  </required_header>
  <id_info>
    <org_study_id>CRN00808-01</org_study_id>
    <nct_id>NCT03276858</nct_id>
  </id_info>
  <brief_title>Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Dose Study to Evaluate the Safety, PK, and PD of CRN00808 in Healthy Volunteers and to Determine the Effect of CRN00808 on Midazolam PK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crinetics Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crinetics Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center study will be conducted in 3 phases: a single-ascending dose phase (up to
      8 cohorts, 8 subjects/cohort), a multiple-dose phase (up to 5 cohorts, 9 subjects/cohort),
      and a midazolam drug-drug interaction phase (one cohort of 8 subjects).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The single-dose phase initiates with ascending doses of an oral solution followed by a 3-way
      crossover food effect and bioavailability (capsule formulation) cohort. Serum IGF-1 levels
      and GHRH-analog stimulated GH levels will be assessed as pharmacodynamics measures.

      The first multiple-dose (7 days dosing) cohort will be initiated after the PK and safety data
      are available from the single-dose phase. Subsequent multiple-dose cohorts will have 10 days
      of dosing. Serum IGF-1 level and GH levels will be assessed as pharmacodynamics measures.

      The last cohort in the study is midazolam drug-drug interaction study. The dose will be
      selected based on review of all pharmacokinetic and safety data for the single-dose and
      multiple-dose cohorts completed. On Day 1, 8 subjects will receive a single oral 2 mg dose of
      midazolam. Starting on Day 3 through Day 8, subjects will receive daily doses of CRN00808. On
      Day 9, subjects will be administered CRN00808 and 2 mg midazolam together.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2017</start_date>
  <completion_date type="Anticipated">May 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single and multiple-dose cohorts are placebo-controlled. The midazolam cohort does not have placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of CRN00808 single ascending doses using clinical assessments, telemetry, and Holter monitoring and subject self-reporting</measure>
    <time_frame>Day 1 through Day 10</time_frame>
    <description>ECG, clinical laboratory parameters, vital signs, physical examinations, telemetry, Holter monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of CRN00808 multiple ascending doses using clinical assessments and subject self-reporting</measure>
    <time_frame>Day 1 through Day 21</time_frame>
    <description>ECG, clinical laboratory parameters, vital signs, physical examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of CRN00808 single ascending doses</measure>
    <time_frame>Day 1 through Day 7</time_frame>
    <description>plasma AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CRN00808 single ascending doses</measure>
    <time_frame>Day 1 through Day 7</time_frame>
    <description>plasma Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CRN00808 single ascending doses</measure>
    <time_frame>Day 1 through Day 7</time_frame>
    <description>plasma t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CRN00808 single ascending doses</measure>
    <time_frame>Day 1 through Day 7</time_frame>
    <description>plasma Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of CRN00808 multiple ascending doses</measure>
    <time_frame>Day 1 through Day 20</time_frame>
    <description>plasma AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CRN00808 multiple ascending doses</measure>
    <time_frame>Day 1 through Day 20</time_frame>
    <description>plasma Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CRN00808 multiple ascending doses</measure>
    <time_frame>Day 1 through Day 20</time_frame>
    <description>plasma t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CRN00808 multiple ascending doses</measure>
    <time_frame>Day 1 through Day 20</time_frame>
    <description>plasma Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of CRN00808 in single ascending dose cohorts assessed by GHRH analog stimulated GH levels</measure>
    <time_frame>Day -1 and Day 1</time_frame>
    <description>Suppression of serum GH induced by a GH secretagogue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of CRN00808 on pharmacokinetics of midazolam</measure>
    <time_frame>Day 1 through Day 10</time_frame>
    <description>midazolam plasma AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of CRN00808 on Cmax of midazolam</measure>
    <time_frame>Day 1 through Day 10</time_frame>
    <description>midazolam plasma Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of CRN00808 on t1/2 of midazolam</measure>
    <time_frame>Day 1 through Day 10</time_frame>
    <description>midazolam plasma t 1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of CRN00808 on Tmax of midazolam</measure>
    <time_frame>Day 1 through Day 10</time_frame>
    <description>midazolam plasma Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative bioavailability of capsule formulation</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>single-dose crossover arm only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on Cmax of CRN00808</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>plasma Cmax compared with and without food in single dose arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on AUC of CRN00808</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Plasma AUC compared with and without food in single dose arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of CRN00808 in multiple ascending dose cohorts assessed by serum IGF-1 and GH</measure>
    <time_frame>Day -1 to Day 21</time_frame>
    <description>serum IGF-1 and GH</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>CRN00808 Oral Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRN00808 oral solution, single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRN00808 Oral Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRN00808 oral capsule, single-dose and multiple-doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral solution, single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule, single-dose and multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam Oral Solution</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRN00808</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>CRN00808 Oral Solution</arm_group_label>
    <arm_group_label>CRN00808 Oral Capsule</arm_group_label>
    <arm_group_label>Midazolam Oral Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Oral Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam oral solution</intervention_name>
    <description>Midazolam as part of the drug-drug interaction arm of the study</description>
    <arm_group_label>Midazolam Oral Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 18 to 30 kg/m2

          -  Females postmenopausal or surgically sterile

        Exclusion Criteria:

          -  Any uncontrolled or active major systemic disease including, but not limited to:
             acromegaly (with or without pituitary surgery or radiation therapy), cardiac,
             pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological,
             psychiatric, or neoplastic disorder with metastatic potential

          -  History or presence of malignancy within the past 5 years. Subjects who have been
             successfully treated (for 3 months or longer) with no recurrence of basal or squamous
             cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled.

          -  Use of any investigational drug within the past 60 days or 5 half-lives, whichever is
             longer

          -  Have a medically significant abnormality observed during screening or the admission
             physical examination or in any other baseline measurements

          -  Use of any prior medication without approval of the investigator within 14 days prior
             to admission

          -  Tested positive at screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis
             C antibody (HCV-Ab) or has a history of a positive result

          -  History of alcohol or substance abuse in the past 6 months

          -  Any condition that in the opinion of the investigator would jeopardize the subject's
             appropriate participation in this Phase 1 study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Lickliter, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajay Madan, PhD</last_name>
    <phone>858-450-6464</phone>
    <email>amadan@crinetics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Struthers, PhD</last_name>
    <phone>858-450-6464</phone>
    <email>sstruthers@crinetics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Lickliter, MBBS PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

